Skip to content
OpenCapital
Get started

Cytek Biosciences, Inc. CTKB Business Segments — Sales (excluding stock-based compensation)

Similar metrics at other companies

BioCryst Pharmaceuticals logo
BCRXReportable Segment — Sales and marketing (excluding stock-based compensation)
$44.27M+16.4%
Yelp logo
YELPReportable Segment — Employee expenses (exclusive of stock-based compensation)
$186.31M+0.3%
Yelp logo
YELPReportable Segment — Cost of revenue (exclusive of depreciation and amortization and stock-based compensation)
$34.64M+17.0%
Shenandoah Telecom logo
SHENReportable Segment — Selling, general and administrative exclusive of stock-based compensation
$28.59M+4.8%
Bakkt logo
BKKTReportable Segment — Non-cash compensation
$2.81M-8.5%
Claritev Corporation logo
CTEVReportable Segment — Personnel expenses excluding stock-based compensation
$51.36M+7.3%

Other financials

Income statement

See full
Revenue$44.1M+6.5%
Gross profit$21.3M+5.4%
Operating income-$18.5M-23.3%
Net income-$18.9M-65.5%
EPS (diluted)-$0.15-66.7%

Balance sheet

See full
Cash & equivalents$31.8M-66.6%
Total debt$16.8M+40.9%
Total equity$327.6M-13.7%
Total assets$449.1M-6.9%

Cash flow

See full
Operating cash flow-$2.7M-2,089%
CapEx$2.2M+155%
Free cash flow-$4.9M-403%

Valuation

See full
Market cap$577.27M+54.5%
Enterprise value$562.23M+93.7%
P/S2.8×+0.9×

Profitability

See full
Gross margin51.7%-3.2pp
Operating margin-21.5%—
Net margin-36.2%—
FCF margin-6.2%-15.1pp

Returns & leverage

See full
Return on equity-20.9%—
Debt / equity0.1×0.0×
Current ratio4.7×-0.9×

Where this comes from

Reported directly by Cytek Biosciences, Inc. in its filing.

Tagged under the XBRL concept ctkb:SellingAndMarketingExpenseExcludingShareBasedPaymentArrangementExpense.

The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytek Biosciences, Inc.'s business segments — sales (excluding stock-based compensation).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cytek Biosciences, Inc.'s business segments — sales (excluding stock-based compensation)?
Cytek Biosciences, Inc. (CTKB) reported business segments — sales (excluding stock-based compensation) of $8.81M in Q1 2026.
How has Cytek Biosciences, Inc.'s business segments — sales (excluding stock-based compensation) changed year-over-year?
Cytek Biosciences, Inc.'s business segments — sales (excluding stock-based compensation) increased by 2.4% year-over-year, from $8.61M to $8.81M.
What is the long-term trend for Cytek Biosciences, Inc.'s business segments — sales (excluding stock-based compensation)?
Over 3 years (2022 to 2025), Cytek Biosciences, Inc.'s business segments — sales (excluding stock-based compensation) has grown at a 25.9% compound annual growth rate (CAGR), from $17.12M to $34.17M.
What does business segments — sales (excluding stock-based compensation) mean?
Captures the cash-based operating expenses associated with the sales and distribution functions of the segment. It provides insight into the cost structure required to acquire and retain customers while excluding the impact of equity-based incentives.